{
    "root": "ca1d9052-2317-4194-986d-9b5786d17a4b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paliperidone",
    "value": "20250225",
    "ingredients": [
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)",
            "code": "5KY68S2577"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 100000",
            "code": "V46Y6OJ5QB"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "paliperidone extended-release tablets atypical antipsychotic agent indicated treatment schizophrenia ( 1.1 ) adults : efficacy established three 6-week trials one maintenance trial . ( 14.1 ) adolescents ( ages 12 17 ) : efficacy established one 6-week trial . ( 14.1 ) treatment schizoaffective disorder monotherapy adjunct mood stabilizers and/or antidepressants . ( 1.2 ) efficacy established two 6-week trials adult patients . ( 14.2 )",
    "contraindications": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 6 mg/day 3 12 mg/day 12 mg/day schizophrenia-adolescents ( 2.1 ) weight < 51 kg 3 mg/day 3 6 mg/day 6 mg/day weight \u2265 51 kg 3 mg/day 3 12 mg/day 12 mg/day schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 12 mg/day 12 mg/day tablet swallowed whole chewed , divided , crushed . ( 2.3 )",
    "warningsAndPrecautions": "paliperidone extended-release tablets , 1.5 mg , supplied brown , round , biconvex tablets , debossed \u201c \u201d \u201c 80 \u201d one side plain side . available follows : bottles 30 : ndc 65162-280-03bottles 90 : ndc 65162-280-09 paliperidone extended-release tablets , 3 mg , supplied white , round , biconvex tablets , debossed \u201c \u201d \u201c 81 \u201d one side plain side.they available follows : bottles 30 : ndc 65162-281-03bottles 90 : ndc 65162-281-09 paliperidone extended-release tablets , 6 mg , supplied light beige , round , biconvex tablets , debossed \u201c \u201d \u201c 82 \u201d one side plain side.they available follows : bottles 30 : ndc 65162-282-03bottles 90 : ndc 65162-282-09 paliperidone extended-release tablets , 9 mg , supplied pink , round , biconvex tablets , debossed \u201c \u201d \u201c 83 \u201d one side plain side.they available follows : bottles 30 : ndc 65162-283-03bottles 90 : ndc 65162-283-09 storage handling store 20\u00b0 25\u00bac ( 68\u00b0 77\u00baf ) ; excursions permitted 15\u00b0 30\u00bac ( 59\u00b0 86\u00baf ) [ usp controlled room temperature ] . protect moisture . keep reach children .",
    "adverseReactions": "paliperidone extended-release tablets contraindicated patients known hypersensitivity either paliperidone risperidone , excipients paliperidone extended-release tablet formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1.1) Adults: Efficacy was established in three 6-week trials and one maintenance trial. (14.1) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. (14.1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (1.2) Efficacy was established in two 6-week trials in adult patients. (14.2)",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults (2.1) 6 mg/day 3 to 12 mg/day 12 mg/day Schizophrenia-adolescents (2.1) Weight < 51 kg 3 mg/day 3 to 6 mg/day 6 mg/day Weight \u2265 51 kg 3 mg/day 3 to 12 mg/day 12 mg/day Schizoaffective disorder - adults (2.2) 6 mg/day 3 to 12 mg/day 12 mg/day Tablet should be swallowed whole and should not be chewed, divided, or crushed. (2.3)",
    "warningsAndPrecautions_original": "Paliperidone extended-release tablets, 1.5 mg, are supplied as brown, round, biconvex tablets, debossed \u201cAN\u201d over \u201c80\u201d on one side and plain on the other side. They are available as follows:\n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-280-03Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-280-09\n                  Paliperidone extended-release tablets, 3 mg, are supplied as white, round, biconvex tablets, debossed \u201cAN\u201d over \u201c81\u201d on one side and plain on the other side.They are available as follows:\n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-281-03Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-281-09\n                  Paliperidone extended-release tablets, 6 mg, are supplied as light beige, round, biconvex tablets, debossed \u201cAN\u201d over \u201c82\u201d on one side and plain on the other side.They are available as follows:\n                  Bottles of 30:\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-282-03Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-282-09\n                  Paliperidone extended-release tablets, 9 mg, are supplied as pink, round, biconvex tablets, debossed \u201cAN\u201d over \u201c83\u201d on one side and plain on the other side.They are available as follows:\n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-283-03Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-283-09\n                  \n                     Storage and Handling \n                  \n                  Store at 20\u00b0 to 25\u00baC (68\u00b0 to 77\u00baF); excursions permitted between 15\u00b0 to 30\u00baC (59\u00b0 to 86\u00baF) [see USP Controlled Room Temperature]. Protect from moisture. \n                  Keep out of reach of children.",
    "adverseReactions_original": "Paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}